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Abstract Frequent expression of cancer testis antigens
(CTA) has been consistently observed in head and neck
squamous cell carcinomas (HNSCC). For instance, in 52
HNSCC patients, MAGE-A3 and -A4 CTA were expressed
in over 75% of tumors, regardless of the sites of primary
tumors such as oral cavity or hypopharynx. Yet, T-cell
responses against these CTA in tumor-bearing patients
have not been investigated in detail. In this study, we
assessed the naturally acquired T-cell response against
MAGE-A3 and -A4 in nonvaccinated HNSCC patients.
Autologous antigen-presenting cells pulsed with overlap-
ping peptide pools were used to detect and isolate MAGE-
A3 and MAGE-A4 speciWc CD4+ T cells from healthy
donors and seven head and neck cancer patients. CD4+
T-cell clones were characterized by cytokine secretion. We
could detect and isolate MAGE-A3 and MAGE-A4 speciWc
CD4+ T cells from 7/7 cancer patients analyzed. Moreover,
we identiWed six previously described and three new
epitopes for MAGE-A3. Among them, the MAGE-A3111–125
and MAGE-A3161–175 epitopes were shown to be naturally
processed and presented by DC in association with HLA-
DP and DR, respectively. All of the detected MAGE-A4
responses were speciWc for new helper epitopes. These data
suggest that naturally acquired CD4+ T-cell responses
against CT antigens often occur in vivo in HNSCC cancer
patients and provide a rationale for the development of
active immunotherapeutic approaches in this type of tumor.
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Abbreviations
pMHC Peptide-MHC
HNSCC Head and neck squamous cell carcinomas
HD Healthy donor
Introduction
Squamous cell carcinoma of the head and neck (HNSCC)
represents the Wfth most common cancer worldwide and is
a signiWcant cause of cancer morbidity and mortality. A
majority of patients with HNSCC present with advanced
disease at the time of Wrst evaluation. While early stages of
HNSCC are generally curable with surgery and chemoradi-
ation, the overall survival for patients with HNSCC is poor
and has not appreciably improved in the past three decades.
Therefore, novel therapeutic approaches are urgently
needed and recent research has focused on the development
of immunotherapy to complement conventional treatments.
Frequent expression of tumor-associated antigens (TAA)
has been repeatedly observed in head and neck carcinomas.
These observations have led to the design of targeted cancer
vaccine trials [1]. TAA are derived from a broad spectrum
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24 Cancer Immunol Immunother (2011) 60:23–35of intracellular proteins. One of the most promising catego-
ries of TAAs is transcriptionally reactivated genes, not
expressed in normal adult host tissues but only present in
germline cells and cancer cells and referred as cancer testis
antigens (CTA). Their highly restricted tissue expression
patterns make them ideal targets for immunotherapy of
numerous cancers. Tumor-speciWc vaccines are thus
designed to generate T-helper and T-cytotoxic lymphocytes
responsive to TAAs. Evidence for the presence of naturally
acquired T-cell responses speciWc for these antigens have
been demonstrated in patients with various cancers but, to
our knowledge, were never studied in HNSCC patients [2–
5]. Generally, the frequency of natural T-cell responses
against CT antigens seems to be relatively low in peripheral
blood of cancer patients. The natural responses are for this
reason diYcult to detect and often require at least one round
of in vitro expansion by stimulation with the antigenic pep-
tide on appropriate antigen-presenting cells to be detected.
Both, the use of overlapping peptide pools and the screening
of responding T cells using diVerent cytokines tend to
increase the level of natural responses detected in cancer
patients that were probably until recently underestimated.
Tumor antigens encoded by the family of MAGE-A
genes are of particular interest in cancer immunotherapy,
because they are expressed in a variety of malignancies.
Among others, these include head and neck squamous cell
carcinoma, melanoma or non-small cell lung carcinoma [6,
7]. In a survey performed by our group, tumor biopsies of 52
HNSCC patients showed that MAGE-A3 or -A4 CTA were
expressed in 75% of the cases, regardless of the sites of pri-
mary tumors such as oral cavity or hypopharynx, conWrming
previous results [8]. Since MAGE-A3 is most frequently
expressed in major tumor types, as mentioned above, it has
been the focus of numerous studies on speciWc T cell-medi-
ated immune responses pre- and post-antigen-speciWc
immunotherapy [9]. A small proportion of cancer bearing
patients naturally develop antibody responses to MAGE-A3,
indicating that this tumor antigen is capable of evoking
spontaneous immune responses [10, 11]. Moreover, epitope-
speciWc memory CD8+ and CD4+ T-cell responses were
rarely detected in cancer patients at relatively low frequen-
cies [12–14]. Very few reports to date have documented the
precise frequency of MAGE-3 speciWc CD4+ T cells natu-
rally arising in cancer patients [10, 15, 16]. MAGE-A4 is as
frequently expressed as MAGE-A3, at least in HNSCC, but
has been far less studied. Despite some data indicating an
inverse correlation of the expression of MAGE-A4 protein
with patient survival [8], no immunotherapeutic protocols
have been conducted, mainly because MAGE-A4 speciWc
T-cell epitopes have not been described yet.
Naturally acquired immunity against these CTA epitopes
in HNSCC patients before vaccination or treatment have not
been investigated in detail; yet, the overall prevalence of
these responses would be informative to optimize further
peptide vaccination clinical trials. In this regard, based on the
MAGE-A3 and -A4 protein tumor expression, a small panel
of HNSCC patients recruited before any therapy were
screened for spontaneous T-cell responses against MAGE-
A3 and MAGE-A4 proteins. Without pre-existing knowl-
edge of epitopes and or restriction elements, total patients’
PBMCs were analyzed for MAGE-A3 and -A4 speciWc
CD4+ T cells. We could detect speciWc CD4+ T-cell
responses against several known as well as undeWned
MAGE-A3 and MAGE-A4 epitopes in PBMC from seven
out of seven patients analyzed after three rounds of in vitro
stimulation with overlapping peptides encoding both pro-
teins. Some of the responding T-cell populations were cloned
and analyzed for MHC restriction and avidity of antigen rec-
ognition. Using speciWc CD4+ T-cell clones, we could also
show that MAGE-A3111–125 and MAGE-A3161–175 epitopes
are naturally processed and presented. We identiWed the
DP1*04 allele as a new MHC II-restricting element for the
MAGE-A3111–125 epitope and we could successfully generate
MAGE-A3111–125/DP1*04 multimer to screen PBMCs and
TILs from an HNSCC patient. Altogether, these Wndings
indicate that MAGE-A3 and -A4 antigens are promising tar-
gets for speciWc immunotherapy of HNSCC.
Materials and methods
Cells and tissue culture
Peripheral blood mononuclear cells (PBMCs) were obtained
from HNSCC patients (Lausanne University Hospital) after
informed consent and from seven healthy donors who
served as controls (Blood Transfusion Center, Berne, Swit-
zerland). Clinical characteristics of the patients included in
this study are described in Table 1. None of the patients
Table 1 Patient characteristics and tumor antigen expression
¡, negative; +, 1–5%; ++, 5–50%; +++, >50% level of expression
a Calculated at the surgery date
b Evaluated by RT–PCR (quantitative assessment was performed
as previously described, using 1:10 dilutions of SK-Mel-37 RNA as
reference [38])
Patients Agea Gender Tumor 
localization
Stage MAGE expressionb
A3 A4
LAU 2032 72 M Oral cavity IV + +++
LAU 2042 69 F Oral cavity III ++ +++
LAU 2068 68 F Oral cavity IV +++ +++
LAU 2069 64 F Oropharynx III +++ ++
LAU 2073 54 M Oropharynx IV +++ ++
LAU 2086 68 M Larynx III ¡ +++
LAU 2091 68 M Oropharynx II ¡ ++123
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autologous tumor cell lines were generated from surgically
removed primary tumor biopsies. Epstein–Barr virus-trans-
formed lymphoblastoid B-cell lines (LCLs) were established
in our laboratory. LCLs and tumor cells were retrovirally
transduced with a pMFG vector encoding huIi80MAGE-
3-Ires-tNGFR [17]. Tumor and LCLs cells were maintained
in continuous in vitro culture in RPMI 1640 medium
(Invitrogen Life Technologies) supplemented with 10%
heat-inactivated FCS (GIBCO, Invitrogen) L-glutamine
(2 mM), penicillin (100 U/ml) and streptomycin (50 g/ml;
Biowhittaker, Walkersville, MD, USA).
HLA typing
HLA class II typing was performed at Geneva’s University
Hospital by J. M. Tiercy, on genomic DNA extracted from
frozen PBLs isolated from patient’s blood samples. HLA-
DR1 and -DQ1 low-resolution typing (two-digit) was
performed by reverse PCR sequence-speciWc oligonucleo-
tide hybridization using Luminex technology (OneLambda;
Ingen). High-resolution typing (four digit) for HLA-DR1,
-DP1 and -DQ1 loci was achieved by PCR sequence-
speciWc primers using Genovision reagents (Milan Analytica).
Synthesis of MAGE-A3 and MAGE-A4 peptides 
and peptide pools
MAGE-A3 and MAGE-A4 15 mers peptides overlapping
by 10 amino acids were synthesized by Proimmune (UK).
Selected sequences were synthesized by the stepwise solid
phase method and synthetic peptides were puriWed by semi-
preparative reverse-phase HPLC. All peptides were >90%
pure as indicated by analytic HPLC. The peptides were
lyophilized, then reconstituted in DMSO at 10 mg/ml or
aliquots of 1 mg/ml and stored at ¡20°C. To reduce the
number of individual peptide stimulation, we generated six
peptide pools with ten peptides each for MAGE-A3 or
MAGE-A4 overlapping peptides.
In vitro propagation of speciWc CD4+ T cells
Twelve pools of 10 MAGE-A3 or MAGE-A4 synthetic pep-
tides were used to stimulate the PBMCs from the HNSCC
patients and HDs. Twenty million PBMCs, depleted for
CD25+ T cells using anti-CD25 microbeads and MiniMACS
magnetic separation columns (Miltenyi Biotec), were cul-
tured for 14 days in RPMI 1640 (Gibco, Grand Island, NY,
USA), supplemented with heat-inactivated pooled human
serum (8%), L-glutamine (2 mM), penicillin (100 U/ml) and
streptomycin (50 g/ml; Biowhittaker, Walkersville, MD,
USA), containing MAGE-A3 or MAGE-A4 peptide pools
(2 M of each peptide). On day two, half medium volume
from each well was removed and replenished with fresh tis-
sue culture medium (TCM) containing interleukin (IL)-2
(150 UI/ml) (Chiron), without any further antigen stimula-
tion. Cultures were expanded for 14 days and restimulated
two more times with the same amount of MAGE-A3 or
MAGE-A4 peptide pools pulsed on irradiated (3,000 rad)
autologous PBMCs as antigen-presenting cells (APCs).
IFN-/TNF- intracellular cytokine staining
On days 7–10 after the third round of simulation, cultures
were tested for the presence of speciWc CD4+ T cells with
the same pool of peptides (2 M each) in an IFN- and
TNF- intracellular cytokine staining assay performed as
follows. Cells were stimulated for 18 h at 37°C in the pres-
ence or absence of the peptide pools and 10 g/ml brefeldin
A (Sigma–Aldrich) was added after the Wrst hour of incuba-
tion. After incubation and washing, cells were stained with
anti-CD4-PE-Cy7 and anti-CD3-APC-Cy7 mAb (Beckman
Dickinson) for 20 min at 4°C, and then Wxed with 1% form-
aldehyde, 2% BSA and 5 mM azide in PBS. Cells were
then stained intracellularly with anti-IFN--PE and anti-
TNF--APC mAb (Beckton Dickinson) in the presence of
0.1% saponin (Sigma–Aldrich). Samples were analyzed by
Xow cytometry on a Facs Array and data were analyzed
using Flow Jo software (Beckton Dickinson).
Generation of clones and antigen recognition assay
CD4+ T cells producing IFN- in the presence of the pool
of peptides were cloned using IFN- and TNF- secretion
assays (Miltenyi Biotec) after 6 h of peptide stimulation
by Xow cytometry-based sorting using a FACSVantage
SE (Becton–Dickinson, Sunnyvale, CA, USA). Sorted
cells were cloned by limiting dilution and growing clones
were screened for IFN- and TFN- release in the pres-
ence or absence of indicated MAGE-A3 or MAGE-A4
peptides.
For each functional assay, 5,000–20,000 of growing
MAGE-A3 or MAGE-A4 speciWc CD4+ T-cell clones were
used. For recognition of indicated target cells, equal num-
bers of antigen-presenting cells or tumor cell lines were
pulsed or not with indicated peptides, extensively washed
and then added to the T cells. In peptide titration experi-
ments, the following concentrations of peptide were added:
50–25–13–6–1.5 and 0.7 M. Where indicated, superna-
tants of anti-HLA-DR (D1.12), -DP (B7.12.1) or -DQ
(BT3.4) were used to speciWcally block MHC class II rec-
ognition. IFN- release was assessed in the culture superna-
tant after 24 h of incubation at 37°C by ELISA (hu IFN-
Cytoset kit; BioSource Europe) following the manufac-
turer’s instructions and using Xat-bottom 96-well Nunc-
Immuno plates (Apogent).123
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labeling
The generation of HLA-DP1*04 multimers was per-
formed as already described [18] using the MAGE-
A3111–125 peptide. Multimer labeling was performed for
1 h at 37°C before staining with Xuorescent mAbs
directed against surface molecules (anti-CD4-FITC)
(20 min at 4°C). PI labeling was used to exclude dead
cells. Cells were analyzed by Xow cytometry on a FAC-
Scan (BD Biosciences) using Cell Quest software (BD
Biosciences).
Results
MAGE-A3 and MAGE-A4 speciWc CD4+ T-cell responses 
in head and neck cancer patients
To assess the naturally acquired anti-tumor T-cell
responses taking place in head and neck squamous cell
carcinomas patients (HNSCC), tumor biopsies were Wrst
screened for tumor-associated antigen expression by
RT–PCR and immunohistochemistry to identify putative
immunogenic antigens. MAGE-A3 and -A4 tumor anti-
gens were speciWcally expressed in about 70% of the
patients (MAGE-A3 in 51%, MAGE-A4 in 60% [8]). We
assessed T-cell responses speciWc for these two well-
represented antigens in peripheral blood from seven
HNSCC patients, selected upon their MAGE-A3 and/or
-A4 high tumor expression (Table 1). BrieXy, CD25+
cell-depleted PBMCs from these patients were stimu-
lated with overlapping peptides covering the entire
sequence of the two proteins. These peptides were 15
amino acids long, overlapping by 10 amino acids and
grouped into six pools containing 10–11 peptides.
CD25+ T-cell depletion was performed prior to stimula-
tion since these cells have been reported to limit the in
vitro expansion of antigen-speciWc CD4+ T cells [19]. A
side-by-side comparison of CD25+ replete and depleted
PBMCs samples was not possible due to the limited
amount of blood allowed by the clinical protocol. After
three rounds of stimulation, the repertoire of epitopes
recognized by polyclonal CD4+ T cells was determined
by testing their reactivity to each pool and then each
peptide forming the pool in a 6-h IFN-/TNF- intracel-
lular cytokine staining (ICS) assay using a Wve-color
immunoXuorescence labeling protocol. The frequency
of CD4+ T cells producing IFN- or TNF- in the
responding patients ranged from 2 to 64% after the third
stimulation. In contrast, undetectable or very low fre-
quency of IFN- or TNF- positive cells was found in
healthy controls and in patients’ PBMCs stimulated with
irrelevant or no peptides (range 0–2%). An example of
the data obtained following this analysis for one patient
and one healthy donor are shown in Fig. 1a.
Among the seven HNSCC patients tested, all of them
showed detectable CD4+ T-cell responses against at least
one MAGE-A3 or MAGE-A4 peptide. Four patients, LAU
2032, LAU 2042, LAU 2073 and LAU 2091, showed
responses against both MAGE-A3 and MAGE-A4 pep-
tides. Responses against MAGE-A3281–295 peptide and
MAGE-A4301–315 peptide appeared simultaneously in two
diVerent patients despite their diVerent class II MHC alle-
les, suggesting recognition of promiscuous epitopes. Most
of the detected MAGE-A3 responses were speciWc to previ-
ously found and/or described epitopes, such as 111–125
and 116–130 [17, 20], region 141–155 [20], 146–160 [20,
21], 161–175 [20, 22] and 281–295 [20, 21]. In contrast,
three responses were speciWc to new epitopes spanning the
regions 156–170, 216–230 and 241–255. All of the
detected MAGE-A4 responses were speciWc to new epi-
topes covering a large part of the protein, from region 116
to 317 (Fig. 1b).
To further characterize these epitopes, clones were
derived from the primary cultures that were able to respond
to short-term stimulation with the selected MAGE-A3 and -
A4 peptides using the IFN-/TNF- capture assay and Xow
cytometry-assisted cell sorting.
CD4+ T-cell responses against MAGE-A3 and -A4 peptides 
are mainly HLA-DR and -DQ restricted
After cloning, ten growing clones that recognized dis-
tinct MAGE-A3 peptides (111–125, 146–160, 161–175,
216–230, 281–295) and MAGE-A4 peptides (271–285,
286–300, 291–305, 301–315, 303–317) could be main-
tained in culture and characterized. To identify the HLA
restricting allele of the diVerent peptide epitopes, grow-
ing CD4+ T-cell clones were tested in short-term stimu-
lation with the selected MAGE-A3 or -A4 peptides in
the presence of either anti-HLA-DR-, -DP- or -DQ-spe-
ciWc Abs known to speciWcally block antigen recogni-
tion. The MAGE-A4291–305 speciWc CD4+ T-cell clone
from LAU 2069 recognized the peptide in an HLA-DR
restricted manner (Fig. 2a). In addition, to identify the
restricting allele, we challenged CD4+ T-cell clones with
a panel of LCLs with identiWed class II MHC, pulsed
with individual peptides. Using diVerent combinations
of presenting LCLs, we could determine that the clone
from LAU 2069 recognized the MAGE-A4291–305
peptide presented by HLA-DR1*13 restricted allele
(Fig. 2b).
Clones from LAU 2091 recognized the MAGE-A3146–160
peptide in an HLA-DR1*07 restricted manner, while they
recognized the MAGE-A4271–285, MAGE-A4301–315 and123
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addition, MAGE-A3111–125 peptide, described as an HLA-
DR1*13 epitope by Chaux et al. [17], appeared to also be
present by the HLA-DP1*04 allele. The clone from LAU
2073 recognized the MAGE-A3281–295 peptide presented by
HLA-DR1*08 and the clone from LAU 2032 recognized
the same peptide presented by HLA-DR1*04. The
MAGE-A3216–230 and MAGE-A4286–300 peptides, recog-
nized by CD4+ T-cell clones from LAU 2032, are presented
by HLA-DR1* 04. Finally, clones from LAU 2068 and
LAU 2069 recognized the MAGE-A3161–175 and MAGE-
A4291–305 peptides presented by HLA-DR1*07 and HLA-
DR1*13, respectively (Fig. 2c).
Characterization of MAGE-A3 and MAGE-A4 speciWc 
CD4+ T-cell clones
To more precisely deWne the epitopes recognized by the
clones from head and neck cancer patients, we stimulated
the MAGE-A3 and MAGE-A4 speciWc CD4+ T-cell clones
with graded amount of peptides followed by assessment of
IFN- production in the culture supernatants. Peptide titra-
tion curves of MAGE-A3146–160 and MAGE-A4301–315 spe-
ciWc CD4+ T-cell clones from LAU 2091 are shown in
Fig. 3a. Both clones recognized their corresponding syn-
thetic peptides with relatively low avidity in the micromo-
lar range (EC50 > 10 M and EC50 > 7 M, respectively).
Fig. 1 Pre-existing CD4+ T-cell responses against MAGE-A3 and
MAGE-A4 antigens in HNSCC patients. a PBLs from HNSCC pa-
tients were stimulated in vitro with MAGE-A3 and MAGE-A4 over-
lapping peptide pools. After three rounds of stimulation, cultures were
tested by intracellular cytokine staining for IFN- and TNF- secretion
in response to the presence of peptide pools. Cytokine secretion of
CD4+ CD3+ lymphocyte gated populations from one HNSCC patient
and one healthy donor in response to peptide pool and individual pep-
tide are shown as example. b Summary of the responses detected after
in vitro stimulation in seven analyzed HNSCC patients. The responses
that could be further cloned by cell sorting and limited dilutions are
indicated as black boxes. Undescribed epitopes are depicted as “NEW”123
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niWcantly recognize the neighboring overlapping peptides
and the corresponding peptide in the MAGE-A4 protein.
The MAGE-A4301–315 speciWc CD4+ T-cell clone recog-
nized also the 303–317 region and failed to signiWcantly
recognize the neighboring overlapping peptides and the
corresponding peptide region in the MAGE-A3 protein
suggesting that the minimal epitope for this clone was
located between the amino acids 303 and 315. The analysis
of the other MAGE-A3 and MAGE-A4 speciWc CD4+
T-cell clones showed that those clones recognized their
respective peptides with low avidity in a micromolar range
(Fig. 3b).
Both MAGE-A3111–125 and MAGE-A3161–175 epitopes 
are naturally processed and presented by the MHC 
class II pathway
We wanted to determine whether the identiWed epitopes
were naturally processed and presented by MHC class
Fig. 2 MHC class II restriction 
of MAGE-A3 and -A4 speciWc 
CD4+ T clones. a Example of 
class II restricted allele assess-
ment on LAU 2069 CD4+ T-cell 
clone 1 speciWc for MAGE-
A4291–305. Where indicated, anti-
DP, DQ, DR puriWed antibodies 
were pre-incubated with cells 
prior to peptide stimulation. 
IFN- release was measured in 
the supernatant by ELISA. 
b Example of Wne HLA II 
restriction performed on LAU 
2069 clone 1. HLA class II 
matched LCL cell lines were 
pulsed (black bars) or not (white 
bars) with MAGE-A4291–305 
peptide and presented to the 
speciWc clone. Recognition of 
the LCL cells with the restricting 
allele was measured by ELISA 
IFN-. c Summary table of 
MHC class II restriction of the 
cloned responses123
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ated after CD14+ cell selection and maturation were used as
APC in peptide recognition assays and pre-incubated with
the MAGE-A3 recombinant protein or with an irrelevant
Flu recombinant protein used as control. As illustrated in
Fig. 4a, monocyte-derived DC were able to eYciently pres-
ent the recombinant MAGE-A3 protein to the CD4+ T-cell
clone from LAU 2068 speciWc for MAGE-A3161–175 pep-
tide on HLA-DR dependent manner, indicating that this
epitope was naturally processed and presented. Unfortu-
nately, MAGE-A4 epitopes could not be studied with this
method since no MAGE-A4 recombinant protein was avail-
able.
The natural processing of diVerent epitopes could also be
assessed using HLA-matched LCLs engineered to express
either MAGE-A3 or MAGE-A4 in the endosomal–lyso-
somal compartment [17]. The MAGE-A3111–125 speciWc
CD4+ T-cell clone from LAU 2091 recognized the peptide
in DP1*04 LCLs transduced with MAGE-A3, conWrming
that the MAGE-A3111–125 peptide was processed through
the class II presentation pathway (Fig. 4b). In addition,
MAGE-A3146–160, MAGE-A3216–230 and MAGE-A3281–295
epitopes were not processed (Fig. 4c). The MAGE-A4286–300
peptide identiWed on CD4+ T cells from LAU 2032 was not
processed by LCLs engineered to express MAGE-A4.
Finally, the processing of MAGE-A4271–285, 301–315 and 303–317
peptides identiWed on CD4+ T cells from LAU 2091 could
not be addressed, since no HLA-DQ LCLs engineered to
express MAGE-A4 were generated. MAGE-A4291–305 epi-
tope could not be addressed since the speciWc clone could
not be maintained in culture (Fig. 4c).
Memory CD4+ T cells speciWc for MAGE-A3111–125/DP4 
are present after in vitro stimulation of PBMCs 
of a HNSCC patient
The MAGE-A3111–125 peptide was used to prepare HLA-
DP1*04 multimer, which was tested on clones gener-
ated from LAU 2091 and additional nonspeciWc clones or
negative controls. Several independent CD4+ T-cell
Fig. 3 Peptide titration and 
cross reactivity of MAGE-A3 
and -A4 speciWc CD4+ T-cell 
clones. a Peptide titration exper-
iments were performed using 
clone-speciWc MAGE-A3 
sequence (open symbol) and 
compared to both neighboring 
overlapping sequences and the 
MAGE-A4 or MAGE-A3 
homologous sequence. Shown 
are IFN- titration curves 
expressed as percentage 
maximal IFN- release of two 
representative clones generated 
from peripheral blood of patient 
LAU 2091. b Summary of the 
EC50 of the diVerent clones123
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by the multimer and no staining was observed on nega-
tive clone 30 (Fig. 5a). In addition, no staining was
observed on irrelevant DP4/tetanus toxoid-speciWc clone 4
(Fig. 5b). We next analyzed ex vivo with the MAGE-
A3111–125 multimer, PBMCs from DP1*04 LAU 2091
patient in which we detected speciWc CD4+ T cells after
in vitro stimulation (Fig. 5c, left panel). No ex vivo
detectable responses against DP4/MAGE-A3111–125 could
be detected in PBMCs and TILs of this patient nor in the
other head and neck cancer patients (data not shown).
Finally, combining the multimer staining with pheno-
typic marker analysis, we analyzed the three in vitro
PBMCs stimulation from LAU 2091 used to generate the
speciWc clones against MAGE-A3111–125 peptide. The
speciWc CD4+ T cells, which were initially detected after
three rounds of in vitro stimulation by cytokine secretion
assays, could already be detected after the Wrst round of
in vitro stimulation by using the HLA-DP1*04/A3111–125
multimer. The speciWc population increased by approxi-
mately fourfold after each stimulation with the peptide
pools from 0.8 to 11%. We found that all MAGE-
A3111–125/DP1*04 tetramer-positive cells had a memory
phenotype, as they were all CD45RA¡. In addition, the
CCR7+ expression was downregulated upon antigenic
stimulation concomitant with the diVerentiation of cen-
tral memory to eVector memory cells (Fig. 5c, right
panel).
Discussion
The main Wnding in this study is the demonstration of fre-
quent naturally acquired T-cell immunity in advanced
Fig. 4 Natural processing and 
presentation of identiWed 
MAGE-A3 and -A4 peptides. 
a Mature HLA-matched den-
dritic cells were activated 
with LPS and pulsed with 5 M 
of recombinant MAGE-A3 
protein. After washing, DCs 
were cocultured with CD4+ 
T-cell clones at 1:1 ratio. IFN- 
production was measured after 
20 h in the supernatant by 
ELISA. Shown are example of 
MAGE-A3 161–175 peptide 
processing by HLA-DRB1*07 
mature DC and presentation to 
LAU 2068 clone 4. 
b Recognition of the endoge-
nous MAGE-A3 antigen was 
assessed upon HLA-matched 
EBV cells transduction with a 
retroviral construct encoding 
Ii.MAGE-A3 and coculture with 
MAGE-A3 peptide-speciWc 
clones. Shown is example of 
LAU 2091 clone 1 speciWc for 
epitope 111–125 cocultured with 
HLA-matched RULE LCL 
transduced with MAGE-A3. 
c Summary table of the 
described epitopes and natural 
processing123
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shared tumor-speciWc antigens in HNSCC, namely MAGE-
A3 and -A4. Indeed, speciWc CD4+ T cells could be readily
expanded from PBLs from all seven HNSCC chosen based
on the expression of the MAGE genes by their tumors. This
was not the case when PBLs from a group of healthy
donors were subjected to the same in vitro stimulation pro-
tocol. Together, our data suggest the existence of memory
responses to MAGE-derived antigens. In support of this
notion, monitoring of MAGE-speciWc T cells using Xuores-
cent multimers during the consecutive in vitro stimulations
showed the presence of expanded T cells already 10 days
after the Wrst round of stimulation with peptides. As is the
case for numerous epitopes derived from tumor antigens,
the frequency of memory T cells is below the detection
limit by multimers-guided Xow cytometry, but can be readily
revealed by in vitro expansion of speciWc cells driven by
the antigen. Exact determination of the actual frequency of
MAGE-speciWc T cells in these patients would require
either limiting dilution analysis coupled to multimer label-
ing, or enrichment of rare multimer events from a large
number of PBLs, as reported in mouse models [23].
While there are several reports identifying multiple epi-
topes recognized by MHC class I restricted MAGE-A4 spe-
ciWc cytotoxic T lymphocytes [24–26], only one paper
identiWed helper epitopes in a peptide derived from the
MAGE-A4 tumor antigen [27]. In the present study, up to
13 distinct class II MAGE-A4 epitopes were recognized by
CD4+ T cells in six to seven patients analyzed. With the
exception of the 281–295 peptide described by Ohkuri
Fig. 5 Detection of MAGE-A3111–125 speciWc CD4+ T-cell clones
with MAGE-A3 111–125/DPB1*04 multimer. a SpeciWc (clones 131,
134, 48) and nonspeciWc (clone 30) clones from LAU 2091 generated
against MAGE-A3111–125 were labeled with DP4/MAGE-A3111–125 -PE
multimer and anti-CD4-FITC antibodies. Cells were gated on live
CD3+ cells. b Fine speciWcity of DP4 tetramer shown by distinct stain-
ing of tetanus toxoid947–960 and MAGE-A3111–125 CD4+ T-cell clones
(clone 4 and 13, respectively) with a combination of DP4/TT947–960-APC
and DP4/MAGE-A3111–125-PE multimers. Cells were gated on live
CD4+ T cells. c DP4/MAGE-A3111–125 speciWc CD4+ T cells detected
after 1, 2 and 3 rounds of in vitro stimulation of the LAU 2091 PBLs
with MAGE-A3 overlapping peptide pools. Left dot plots PBLs were
screened with the tetramer and gated on live CD4+ T cells. Right dot
plots phenotype of CD4+ tetramer T-cell populations analyzed by
CD45RA and CCR7 staining. All dot plots are gated on live cells123
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epitopes. We obtained clonal CD4+ T-cell populations speciWc
for Wve epitopes (MAGE-A4: 271–285, 286–300, 291–305,
301–315 and 303–317) presented by HLA class II
DQ1*02, DR1*04, DR1*13, DQ1*02 and DQ1*02,
respectively. Some of these peptides may, however, be pre-
sented by more than one MHC class II molecule. For
instance, speciWc CD4+ T cells against the MAGE-A4301–315
epitope were observed in two cancer patients. In one
patient, LAU 2091, the epitope was presented by HLA-
DQ1*02. However, the second patient, LAU 2073, was
HLA-DQ1*02 negative, thus implying that speciWc T-cell
recognition involves a diVerent MHC class II allele.
Only one HLA-matched LCL engineered to express
MAGE-A4 in the endosomal–lysosomal compartment
could be tested for natural processing and presentation of
MAGE-A4 epitopes. However, the MAGE-A4286–300 spe-
ciWc CD4+ T-cell clone did not detectably recognize this
MAGE-A4 expressing LCL. These results might suggest
that the peptide is not eYciently processed in the endo-
somal compartment of transduced B cells. In this regard,
the other report on MAGE-4 helper-speciWc T cells used
autologous monocytes-derived dendritic cells pulsed with
the recombinant MAGE-A4 protein to determine speciWc
MAGE-A4 CD4+ T cells and used overlapping peptides to
identify the minimal MAGE-A4284–293 epitope [27]. This
Wnding indicates that peptides in this region of the protein
can be processed for MHC class II loading and presentation
to T cells. Thus, an alternative possibility is that the CD4+
T-cell clones obtained from cancer patients used in this
study are of too low avidity to pick up processed peptides in
MAGE-A4 transduced B cells.
In contrast to MAGE-A4 epitopes, MAGE-A3 epitopes
have been extensively studied in terms of speciWc T-cell
responses. Indeed, several class I and class II epitopes have
been described both in healthy donor and in cancer patients.
In this study, we could detect CD4+ T-cell responses
against six previously described MAGE-A3 epitopes (111–
125, 116–130, 141–155, 146–160, 161–175 and 281–295)
as well as three new epitopes (MAGE-A3: 156–170, 216–
230 and 241–255). The MAGE-A3111–125 and MAGE
A3161–175 peptides appeared to be immunodominant
epitopes. Indeed, these were shown to be naturally
processed by diVerent types of APCs and presented by
HLA-DP1*04 and HLA-DR1*07, respectively. The
MAGE-A3111–125 epitope has been identiWed Wrst as an epi-
tope presented by HLA-DR13 [17], then also by HLA-DR1,
HLA-DR4, HLA-DR11 and HLA-DR7 molecules [20].
The MAGE-A3111–125 peptide is therefore another example
of a promiscuous CD4+ T-cell epitope. Our data show that
in addition to presentation by multiple HLA-DR allelic prod-
ucts, this peptide can also be presented by HLA-DP4. The
HLA-DP1*04 allele is expressed by approximately 60%
of the Caucasian population and covers, together with the
frequent HLA-DR1*01 (20%), HLA-DR1*04 (27%),
HLA-DR1*07 (27%), HLA-DR1*11 (19%) and HLA-
DR1*13 (21%) alleles, a signiWcant fraction of Caucasian
patients. Moreover, the MAGE-A3 sequence 111–125 con-
tains also the HLA-A2 (MAGE-A3112–120) binding epitope
[28]. We demonstrated here the ability of Xuorescent DP4/
MAGE-A3111–125 peptide multimers to identify speciWc
CD4+ T cells propagated in vitro, thus opening the way to
monitoring of these responses.
Concerning the MAGE-A3161–175 sequence, several pre-
dicted MHC class II binding epitopes have been described
[22]. It also contains HLA-A1 (MAGE-A3168–176) and
HLA-B44 (MAGE-A3167–175) restricted epitopes [29], sug-
gesting an interesting peptide for vaccination. However,
natural processing of the class II peptide could not be dem-
onstrated in one study [20]. Another group reported that it
was poorly formed and did not Wnd evidence of speciWc
CD4+ T-cell responses in advanced melanoma patients
[22]. Our results are in sharp contrast with these previous
reports since we could detect speciWc CD4+ T cells and
could also show recognition of processed recombinant
MAGE-A3 protein. These discrepancies may be due to the
diVerent types of cancer.
In contrast to the former epitopes, the MAGE-A3146–160
speciWc, MAGE-A3216–230 speciWc and MAGE-A3281–295
speciWc CD4+ T cells failed to recognize in vitro the
MAGE-A3 protein after processing by autologous dendritic
cells. However, reports from other groups showed eYcient
processing of the MAGE-A3146–160 and MAGE-A3281–295
epitopes [20, 21, 30]. Again, it might be that the CD4 T-cell
clones recovered from this series of head and neck cancer
patients bear TCRs of relatively low avidity.
Despite recognition of processed peptides in recombi-
nant protein fed, or MAGE-A3 transduced antigen-present-
ing cells, no tumor recognition could be demonstrated in
the few CD4+ T-cell clone/tumor combinations that could
be tested (Table 2 and data not shown). This could not be
explained by lack of expression of MHC class II molecules,
as expression could be detected at the cell surface and their
levels could be increased upon IFN- treatment. These
results suggest that priming of the memory responses
detected in cancer patients probably required processing
and presentation by professional APCs from internalized
apoptotic tumor cells. They also imply indirect antigen rec-
ognition by eVector CD4+ T cells at the tumor sites. How-
ever, it cannot be excluded that high avidity CD4+ T cells
against at least some of the MAGE-derived epitopes can
directly recognize MHC class II tumor cells. This possibil-
ity is reinforced by reports from other groups who have
succeeded in showing direct tumor antigen recognition by
MAGE antigen-speciWc CD4+ T cells. Concerning the rela-
tionship between MAGE-A3 or -A4 expression and the123
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but one responding patients expressed the target gene prod-
uct (Table 1). The single exception may simply reXect the
incomplete covering of antigen expression by the small
biopsy that may not be representative of the entire tumor
mass.
Epitope-speciWc CD8 T-cell responses were rarely
detected from freshly isolated peripheral blood in cancer
patients and was found to be quite low before vaccination
[12, 14, 31]. However, only after in vitro culture or 3 weeks
post-vaccination, CD8+ T cell could be expanded and their
functional status estimated [10, 32]. The apparent paucity
of MAGE-speciWc CD8+ T-cell responses in this series
of HNSCC patients might suggest the existence of CD8+
T-cell tolerance to these antigens. However, we favor the
possibility that this paucity only reXects the inadequacy of
peptide pools made of 15-mer peptides to eYciently expand
not only CD4+ T cells, but also MHC class I restricted
CD8+ T cells. To address this issue, we are planning to
revisit MAGE-speciWc CD8+ T-cell responses in these
patients using pools of nine and ten amino acid long syn-
thetic peptides covering the MAGE-A3 and -A4 proteins.
In all, very few reports to date have documented the pre-
cise frequency of MAGE-A3 speciWc CD4+ T cells natu-
rally arising in cancer patients and none for MAGE-A4. By
studying a large panel of cytokine produced by peripheral
PBLs in responses to tumor-associated antigens, Inokuma
et al. [15] were able to detect ex vivo signiWcant CD8 and
CD4 T-cell responses against MAGE-A3 in 17/23 breast
cancer patients naïve to immunotherapy. Similarly, another
study reported the baseline level of CD4+ T-cell responses
prior MAGE-A3 protein and adjuvant immunization of
melanoma patients and could detect MAGE-A3 speciWc
helper T-cell responses in 3/16 patient before vaccination
[16]. In contrast, Atanackovic et al. [10] found only 1 out of
18 non-small cell lung cancer patients vaccinated with
MAGE-A3 protein and adjuvant, having a pre-existing anti-
body response against MAGE-A3 protein as well as CD4
T-cell responses to MAGE-A3 DP4 epitope (p243–258).
Globally, spontaneous and detectable anti-MAGE-A3
responses seem to be a rare event in cancer patients; how-
ever, some patients may have mounted a response below
the detection level of the techniques used at the time of
analysis. In our experiments, the requirement of three con-
secutive rounds of in vitro stimulation to detect MAGE-A3/
A4 speciWc CD4+ T cells reXect a relatively low frequency
of these cells as conWrmed by the ex vivo absence of detect-
able DP4/MAGE-A3111–125 peptide multimer+ CD4+ T
cells. However, it is also likely that these CD4+ T cells were
anergic in vivo and reacquired full functional competence
upon repeated in vitro stimulation with speciWc peptide and
IL-2. In agreement with this notion, HNSCC have indeed
been shown to be highly immunosuppressive tumors.
Among the many immunosuppressive mechanisms, the
impairment of T-cell activation and the production of
immune inhibitory mediators by the tumors have been fre-
quently observed in HNSCC [33–35] and would Wt with the
generation of low avidity of CD4+ T cells as detected in this
study.
Vaccination with class II MAGE-A3 speciWc peptide or
recombinant MAGE-A3 proteins have shown no signiWcant
toxicity and has led to the induction of strong tumor-spe-
ciWc CD4+ T-cell responses [10, 16, 36, 37]. Thus, targeting
MAGE-A3 and/or -A4 for immunotherapy is an attractive
possibility in patients with HNSSC tumors. Sequences such
as MAGE-A3111–125 and MAGE-A3161–175 bear naturally
processed epitopes that are recognized by both MHC class
II restricted CD4+ T cells and MHC class I restricted CD8+
T cells. Approaches to antigen delivery such as recombi-
nant protein or long synthetic peptides may provide potent
immunogens able to induce broad T-cell responses in a
large segment of the patient population, thus alleviating the
constraints imposed by MHC restriction. These results also
provide a useful baseline for future immunomonitoring
studies in vaccinated patients.
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